These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 38334387)

  • 1. Intranasal SARS-CoV-2 RBD decorated nanoparticle vaccine enhances viral clearance in the Syrian hamster model.
    Patel DR; Minns AM; Sim DG; Field CJ; Kerr AE; Heinly TA; Luley EH; Rossi RM; Bator CM; Moustafa IM; Norton EB; Hafenstein SL; Lindner SE; Sutton TC
    Microbiol Spectr; 2024 Mar; 12(3):e0499822. PubMed ID: 38334387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intranasal SARS-CoV-2 RBD decorated nanoparticle vaccine enhances viral clearance in the Syrian hamster model.
    Patel DR; Minns AM; Sim DG; Field CJ; Kerr AE; Heinly T; Luley EH; Rossi RM; Bator C; Moustafa IM; Hafenstein SL; Lindner SE; Sutton TC
    bioRxiv; 2022 Dec; ():. PubMed ID: 36324809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intranasal immunization with the recombinant measles virus encoding the spike protein of SARS-CoV-2 confers protective immunity against COVID-19 in hamsters.
    Park SI; Park S; Lee K; Kwak HW; Kim YK; Park HJ; Bang YJ; Kim JY; Kim D; Seo KW; Lee SJ; Kim H; Kim Y; Kim DH; Park HJ; Jung SY; Ga E; Hwang J; Na W; Hong SH; Lee SM; Nam JH
    Vaccine; 2024 Jan; 42(2):69-74. PubMed ID: 38097457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Intranasal OMV-Based Vaccine Induces High Mucosal and Systemic Protecting Immunity Against a SARS-CoV-2 Infection.
    van der Ley PA; Zariri A; van Riet E; Oosterhoff D; Kruiswijk CP
    Front Immunol; 2021; 12():781280. PubMed ID: 34987509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prototype and BA.5 protein nanoparticle vaccines protect against Omicron BA.5 variant in Syrian hamsters.
    Bricker TL; Joshi A; Soudani N; Scheaffer SM; Patel N; Guebre-Xabier M; Smith G; Diamond MS; Boon ACM
    J Virol; 2024 Mar; 98(3):e0120623. PubMed ID: 38305154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An intranasal vaccine comprising SARS-CoV-2 spike receptor-binding domain protein entrapped in mannose-conjugated chitosan nanoparticle provides protection in hamsters.
    Tabynov K; Solomadin M; Turebekov N; Babayeva M; Fomin G; Yadagiri G; Renu S; Yerubayev T; Petrovsky N; Renukaradhya GJ; Tabynov K
    Sci Rep; 2023 Jul; 13(1):12115. PubMed ID: 37495639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Efficacy of Combined Intramuscular/Intranasal RAZI-COV PARS Vaccine Candidate Against SARS-CoV-2: A Preclinical Study in Several Animal Models.
    Banihashemi SR; Es-Haghi A; Fallah Mehrabadi MH; Nofeli M; Mokarram AR; Ranjbar A; Salman M; Hajimoradi M; Razaz SH; Taghdiri M; Bagheri M; Dadar M; Hassan ZM; Eslampanah M; Salehi Najafabadi Z; Lotfi M; Khorasani A; Rahmani F
    Front Immunol; 2022; 13():836745. PubMed ID: 35693788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. One dose of COVID-19 nanoparticle vaccine REVC-128 protects against SARS-CoV-2 challenge at two weeks post-immunization.
    Gu M; Torres JL; Li Y; Van Ry A; Greenhouse J; Wallace S; Chiang CI; Pessaint L; Jackson AM; Porto M; Kar S; Li Y; Ward AB; Wang Y
    Emerg Microbes Infect; 2021 Dec; 10(1):2016-2029. PubMed ID: 34651563
    [No Abstract]   [Full Text] [Related]  

  • 9. The Influence of Adjuvant Type on the Immunogenicity of RBD/N Cocktail Antigens as a Vaccine Candidate against SARS-CoV-2 Virus.
    Brzuska G; Zimna M; Baranska K; Szewczyk B; Strakova P; Ruzek D; Krol E
    Microbiol Spectr; 2023 Jun; 11(3):e0256422. PubMed ID: 37199661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intranasal nanoemulsion adjuvanted S-2P vaccine demonstrates protection in hamsters and induces systemic, cell-mediated and mucosal immunity in mice.
    Ganesan S; Acosta H; Brigolin C; Orange K; Trabbic K; Chen C; Lien CE; Lin YJ; Lin MY; Chuang YS; Fattom A; Bitko V
    PLoS One; 2022; 17(11):e0272594. PubMed ID: 36322572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced mucosal immune responses and reduced viral load in the respiratory tract of ferrets to intranasal lipid nanoparticle-based SARS-CoV-2 proteins and mRNA vaccines.
    Boley PA; Lee CM; Schrock J; Yadav KK; Patil V; Suresh R; Lu S; Feng MM; Hanson J; Channappanavar R; Kenney SP; Renukaradhya GJ
    J Nanobiotechnology; 2023 Feb; 21(1):60. PubMed ID: 36814238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.
    Zhang J; Han ZB; Liang Y; Zhang XF; Jin YQ; Du LF; Shao S; Wang H; Hou JW; Xu K; Lei W; Lei ZH; Liu ZM; Zhang J; Hou YN; Liu N; Shen FJ; Wu JJ; Zheng X; Li XY; Li X; Huang WJ; Wu GZ; Su JG; Li QM
    Elife; 2022 Aug; 11():. PubMed ID: 36004719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A bacterial extracellular vesicle-based intranasal vaccine against SARS-CoV-2 protects against disease and elicits neutralizing antibodies to wild-type and Delta variants.
    Jiang L; Driedonks TAP; Jong WSP; Dhakal S; Bart van den Berg van Saparoea H; Sitaras I; Zhou R; Caputo C; Littlefield K; Lowman M; Chen M; Lima G; Gololobova O; Smith B; Mahairaki V; Riley Richardson M; Mulka KR; Lane AP; Klein SL; Pekosz A; Brayton C; Mankowski JL; Luirink J; Villano JS; Witwer KW
    J Extracell Vesicles; 2022 Mar; 11(3):e12192. PubMed ID: 35289114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Newcastle Disease Virus (NDV)-based vaccine candidate against SARS-CoV-2 Omicron by intranasal immunization.
    Zhang QY; Zhang HQ; Zhang YN; Zhang ZR; Li XD; Hao MC; Zhang Y; Li JQ; Hu YY; Chen XL; Wang J; Shi YJ; Deng CL; Chen JJ; Ye HQ; Zhang B
    Antiviral Res; 2023 Dec; 220():105757. PubMed ID: 37984567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Methyltransferase-Defective Vesicular Stomatitis Virus-Based SARS-CoV-2 Vaccine Candidate Provides Complete Protection against SARS-CoV-2 Infection in Hamsters.
    Lu M; Zhang Y; Dravid P; Li A; Zeng C; Kc M; Trivedi S; Sharma H; Chaiwatpongsakorn S; Zani A; Kenney A; Cai C; Ye C; Liang X; Qiu J; Martinez-Sobrido L; Yount JS; Boyaka PN; Liu SL; Peeples ME; Kapoor A; Li J
    J Virol; 2021 Sep; 95(20):e0059221. PubMed ID: 34379509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intranasal Delivery of Thermostable Subunit Vaccine for Cross-Reactive Mucosal and Systemic Antibody Responses Against SARS-CoV-2.
    Nguyen KG; Mantooth SM; Vrabel MR; Zaharoff DA
    Front Immunol; 2022; 13():858904. PubMed ID: 35592324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical immunogenicity and efficacy of a candidate COVID-19 vaccine based on a vesicular stomatitis virus-SARS-CoV-2 chimera.
    Espeseth AS; Yuan M; Citron M; Reiserova L; Morrow G; Wilson A; Horton M; Rukhman M; Kinek K; Hou F; Li SL; Li F; Choi Y; Heidecker G; Luo B; Wu G; Zhang L; Strable E; DeStefano J; Secore S; Mukhopadhyay TK; Richardson DD; Sayeed E; Welch LS; Bett AJ; Feinberg MB; Gupta SB; Cooper CL; Parks CL
    EBioMedicine; 2022 Aug; 82():104203. PubMed ID: 35915046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intranasal VLP-RBD vaccine adjuvanted with BECC470 confers immunity against Delta SARS-CoV-2 challenge in K18-hACE2-mice.
    Lee KS; Rader NA; Miller-Stump OA; Cooper M; Wong TY; Shahrier Amin M; Barbier M; Bevere JR; Ernst RK; Heath Damron F
    Vaccine; 2023 Jul; 41(34):5003-5017. PubMed ID: 37407405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intranasal administration of unadjuvanted SARS-CoV-2 spike antigen boosts antigen-specific immune responses induced by parenteral protein subunit vaccine prime in mice and hamsters.
    Agbayani G; Akache B; Renner TM; Tran A; Stuible M; Dudani R; Harrison BA; Duque D; Bavananthasivam J; Deschatelets L; Hemraz UD; Régnier S; Durocher Y; McCluskie MJ
    Eur J Immunol; 2024 Jun; 54(6):e2350620. PubMed ID: 38561974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intranasal administration of adenoviral vaccines expressing SARS-CoV-2 spike protein improves vaccine immunity in mouse models.
    Freitag TL; Fagerlund R; Karam NL; Leppänen VM; Ugurlu H; Kant R; Mäkinen P; Tawfek A; Jha SK; Strandin T; Leskinen K; Hepojoki J; Kesti T; Kareinen L; Kuivanen S; Koivulehto E; Sormunen A; Laidinen S; Khattab A; Saavalainen P; Meri S; Kipar A; Sironen T; Vapalahti O; Alitalo K; Ylä-Herttuala S; Saksela K
    Vaccine; 2023 May; 41(20):3233-3246. PubMed ID: 37085458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.